Work

NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-201677

Authors: Christopher J. Forlenza, David Hoogstra, Donald Barkauskas, Lauren Saguilig, Suzanne D. Turner, Nina Prokoph, Perla Pucci, Lucy Hare, Leila Jahangiri, Rui Wu, Kojo S.J. Elenitoba-Johnson, Eric J. Lowe, Megan S. Lim

Institutions: Memorial Sloan Kettering Cancer Center, Spectrum Health, Helen DeVos Children's Hospital, Children's Oncology Group, University of Cambridge, Children's Hospital of The King's Daughters

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405042529

Cites:

Cited by:

Related to: 10